



Keto acid profiling analysis as ethoxime/*tert*-butyldimethylsilyl derivatives by gas chromatography–mass spectrometry

Duc-Toan Nguyen^a, Gwang Lee^{a,b,1}, Man-Jeong Paik^{c,*}

^a Department of Molecular Science and Technology, Ajou University, Suwon 443-721, Republic of Korea

^b Institute for Medical Science, School of Medicine, Ajou University, Suwon 443-721, Republic of Korea

^c College of Pharmacy, Suncheon National University, Suncheon 540-950, Republic of Korea

ARTICLE INFO

Article history:

Received 7 July 2012

Accepted 5 November 2012

Available online 29 November 2012

Keywords:

Keto acid

Ethoxime/*tert*-butyldimethylsilyl

derivatives

Gas chromatography–mass spectrometry

Plasma

Urine

Brain tissue

ABSTRACT

Organic acids, including keto acids, are key intermediates of central pathways in cellular metabolism. In this study, a comprehensive and reliable method was developed and optimized for the simultaneous measurement of 17 keto acids in various biological samples. The keto acids were converted to solvent extractable forms by ethoximation followed by *tert*-butyldimethylsilylation for direct analysis by gas chromatography–mass spectrometry in selected ion monitoring mode. The proposed method was precise (0.05–8.3, % RSD) and accurate (–10.5 to 5.3, % RE) with low limit of detection (0.01–0.5 ng/mL) and good linearity ($r > 0.995$) in the range of 0.01–5.0 $\mu\text{g/mL}$. This was suitable for profiling analysis of targeted keto acids in human plasma, urine and rat brain tissue.

© 2012 Elsevier B.V. All rights reserved.

1. Introduction

Organic acids are the most diverse and prominent metabolites that exhibit a vital role in the intermediary metabolism. They are involved in major pathways in biological systems such as the tricarboxylic acid (TCA) cycle, fatty acid β -oxidation, and amino acid metabolism. Changes in the organic acids levels are associated with a variety of metabolic disorders such as diabetes mellitus, maple syrup urine disease (MSUD), organic acidopathies, organic acidemias, and ketoacidosis [1–3]. In particular, MSUD is caused by deficiency of the branched-chain α -ketoacid dehydrogenase, which leads to disruption in the conversion of the branched-chain amino acids such as leucine, isoleucine, and valine to α -ketoisocaproic acid, α -keto- β -methylvaleric acid and α -ketoisovaleric acid, respectively. These α -keto acids play an important role in equilibrium with their precursor amino acids

[2–5]. Another important keto acid, acetoacetic acid is accumulated during fatty acid metabolism when glucose is not readily available. Acetoacetate serves as a crucial metabolic fuel and plays a key role in sparing glucose utilization, especially, provides an alternative source of energy for the brain during periods of glucose deficiency. Abnormally large quantities of ketone bodies are found in patients with ketoacidosis, therefore ketone bodies have been used as markers of energy metabolism [6]. Pyruvic acid is a precursor of acetyl coenzyme A, which is the primary material for energy production via the TCA cycle. Other keto acids such as α -ketoglutaric acid and oxaloacetic acid are both vital intermediates of amino acid metabolism and the TCA cycle. Abnormal levels of these keto acids and organic acid intermediates are frequently associated with TCA cycle dysfunction and enzyme deficiency, which are causes of various diseases including tumor in human [1,2,7,8].

The most important objective of quantitative analysis of organic acids is to detect negligible changes in metabolite profiles between normal and abnormal, physiological and pathological states [9], which provide valuable information for insight into the metabolic pathways as well as for screening of metabolic disorders. The development of sensitive, rapid and comprehensive techniques is required for simultaneous quantitative measurement of an enormous number of organic acids in physiological fluids. Due to its high sensitivity, high resolution, accuracy and reliability, gas chromatography–mass spectrometry (GC–MS) is a powerful technique and has been widely used for metabolic profiling analysis in

Abbreviations: TCA, tricarboxylic acid; MSUD, maple syrup urine disease; GC–MS, gas chromatography–mass spectrometry; MO/TMS, methoxime/trimethylsilyl; EO, ethoxime; TBDMS, *tert*-butyldimethylsilyl; SIM, selected ion monitoring; IS, internal standard; TDPA, 3,3'-thiodipropionic acid; MTBSTFA, N-methyl-N-(*tert*-butyldimethylsilyl)trifluoroacetamide; RSD, relative standard deviation; RE, relative error; LOD, limit of detection.

* Corresponding author. Tel.: +82 61 750 3762; fax: +82 61 750 3708.

E-mail addresses: paik815@sunchon.ac.kr, paik815@hanmail.net (M.-J. Paik).

¹ Co-corresponding author.

acids, which reached maximum reaction yield at 80 °C, and oxaloacetic acid at 90 °C, the highest reaction yields of most compounds were obtained at 60 °C. The yield from most keto acids was significantly decreased when the reaction mixture was heated to 80 °C and 90 °C, probably due to decomposition of unstable keto acids or loss of volatile EO derivatives at high temperature. The ketomalonic acid peak nearly disappeared when the reaction was performed at 80 °C and 90 °C. Therefore, the optimum temperature was around 60 °C, and another experimental set was carried out at 60 °C for 10, 30, 60, 90 and 120 min to assess the effect of reaction time. As summarized in Table 5, the maximum responses of keto acids were obtained at either 30 min or 60 min. Improvements in yields were not achieved by increasing or decreasing the heating time. A longer reaction time (90 min) reduced the yield, while a shorter heating (10 min) resulted in lower yield with the exception of ketomalonic acid. There were no considerable differences in response between reaction times of 30 min and 60 min, therefore 30 min were selected for subsequent experiments.

The obtained results suggested that reaction temperature was an important factor that could affect the EO derivatization process in aqueous phase; 60 °C was the most suitable temperature. The reaction time also had some effect; however it did not strongly affect the reaction yield of keto acids. In summary, the optimal conditions for EO reaction from this work were achieved in aqueous media at neutral pH in the presence of ethoxyamine (5 mg) and TDPA (100 µg) at 60 °C for 30 min.

3.2.4. Stability of the EO/TBDMS derivatives

The stability of the EO/TBDMS derivatives was determined by repeated evaluation of the peak area ratio of keto acid standards to IS that were stored in the refrigerator at 4 °C and thawed at room temperature for 1 h prior to injection. All the EO/TBDMS derivatives of keto acids exhibited good stability for at least 20 days when stored at 0 °C in sealed vials.

3.3. Method validation for measurement of keto acids

The SIM chromatogram of keto acids from the standard mixture is shown in Fig. 1. The calibration curves of 17 keto acids ranging from 0.01 to 5.0 µg/mL under optimal conditions were linear with regression coefficients better than 0.995 and good LODs (0.01–0.5 ng/mL), precision and accuracy. The intra-day and inter-day precision (% RSD) of this profiling method was 0.3–4.3 and 0.05–8.3 at different levels of 0.5 and 5.0 µg/mL, respectively. The accuracy (% RE) measured at two different concentrations were –10.3 to 4.8 for intra-day and –10.5 to 5.3 for inter-day. These were acceptable for quantitative measurement of keto acids from biological samples (Table 6).

3.4. Profiling analysis of keto acids

Good chromatographic profiles were obtained when the present method was applied to analyze urine, plasma and tissue samples (Fig. 1). A total of 17 keto acids were positively identified and quantified from these samples by GC–MS in SIM mode.

In conclusion, a selective and sensitive GC–MS method for measurement of keto acids as EO/TBDMS derivatives was developed. The present method exhibited several advantages: it allowed simultaneous determination of keto acids from various biological samples, and its overall linearity, precision, and accuracy indicated suitability and applicability of the method for recovery and quantitative analysis of these compounds from aqueous matrixes. The method also appeared to be sensitive with LODs at nanogram levels. We confirmed that the method can be applied for profiling analysis of keto acids present in urine, plasma and tissue for detection of biological markers as well as rapid monitoring of

Table 6
Validation data of keto acids as ethoxime/tert-butyl(dimethylsilyl) derivatives.

No.	Compound	Linearity (r) ^a	LOD ^b (ng/mL)	Added (µg/mL)	Intra day			Inter day				
					Precision (% RSD) ^c	Accuracy (% RE) ^d	Precision (% RSD)	Accuracy (% RE)	Precision (% RSD)	Accuracy (% RE)		
1	Glyoxylic acid	0.9990	0.5	0.5	0.3	–1.0	1.2	0.2	2.8	–4.9	1.1	–5.9
2	Pyruvic acid	0.9981	0.2	0.5	3.2	0.8	0.6	–1.0	3.8	–7.6	1.8	–9.5
3	α-Ketobutyric acid	0.9974	0.01	0.5	1.6	–4.3	2.2	–6.1	1.8	2.5	3.2	–1.2
4	α-Ketoisovaleric acid	0.9993	0.04	0.5	2.1	–2.6	4.5	0.4	1.0	–3.9	0.7	–4.2
5	Acetoacetic acid	0.9997	0.07	0.5	3.8	4.8	8.3	2.9	3.3	0.4	2.0	2.2
6	α-Ketovaleric acid	0.9970	0.02	0.5	2.4	–8.6	1.9	–6.7	2.6	2.6	1.6	3.8
7	α-Ketocaproic acid	0.9973	0.1	0.5	0.5	–2.5	2.1	–0.3	1.3	–9.8	2.0	–9.5
8	α-Keto-β-methylvaleric acid	0.9973	0.2	0.5	0.5	–2.6	2.1	–0.3	1.4	–9.8	2.0	–9.5
9	α-Ketocaproic acid	0.9967	0.2	0.5	0.6	–8.7	4.0	–4.3	2.8	2.8	0.05	2.7
10	α-Ketooctanoic acid	0.9972	0.04	0.5	1.0	–5.6	2.5	–3.2	4.3	–8.8	1.5	–9.6
11	α-Keto-γ-methylbutyric acid	0.9994	0.2	0.5	1.2	–9.3	2.3	–7.2	1.4	0.5	0.2	0.4
12	Ketomalonic acid	0.9957	0.02	0.5	0.9	–9.6	7.7	–0.8	1.1	2.4	2.5	5.3
13	Oxaloacetic acid	0.9999	0.4	0.5	3.7	4.3	5.1	–0.6	0.7	2.1	3.1	4.9
14	α-Ketoglutaric acid	0.9975	0.03	0.5	0.2	–8.3	4.1	–4.2	1.7	–8.1	0.5	–7.6
15	α-Ketoadipic acid	0.9951	0.01	0.5	1.4	–9.8	1.3	–10.5	1.4	3.3	0.9	4.4
16	β-Ketoadipic acid	0.9951	0.01	0.5	1.3	–10.3	1.8	–10.2	1.3	3.5	1.0	4.2
17	γ-Ketopimelic acid	0.9974	0.01	0.5	0.8	–8.6	2.2	–6.7	1.0	2.4	1.0	1.5

^a Correlation coefficients in the calibration range of 0.01–5.0 µg/mL.

^b Limit of detection.

^c Relative standard deviation.

^d Relative error.




Fig. 1. SIM chromatogram of keto acids as ethoxime/*tert*-butyldimethylsilyl derivatives of standard mixture (A), rat brain tissue (B), normal human urine (C) and normal human plasma (D): IS, 3,4-dimethoxybenzoic acid; 1, glyoxylic acid; 2, pyruvic acid; 3, α -ketobutyric acid; 4, α -ketoisovaleric acid; 5, acetoacetic acid; 6, α -ketovaleric acid; 7, α -ketoisocaproic acid; 8, α -keto- β -methylvaleric acid; 9, α -ketocaproic acid; 10, α -ketoctanoic acid; 11, α -keto- γ -methylbutyric acid; 12, ketomalonic acid; 13, oxaloacetic acid; 14, α -ketoglutaric acid; 15, α -keto adipic acid; 16, β -keto adipic acid; 17, γ -ketopimelic acid.

levels associated with diseases such as the metabolic disorders. The method will be useful for investigating the changes in the metabolic profile in abnormal physiological states.

Acknowledgements

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science, and Technology (2010-0021443 and 2012R1A1A2007846) to M.J. Paik and (2010-0023846) to G. Lee. And the Priority Research Centers Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012-0006687).

References

- [1] G.F. Hoffmann, P. Feyh, in: N. Blau, M. Duran, M.E. Blaskovics, K.M. Gibson (Eds.), *Physician's Guide to the Laboratory Diagnosis of Metabolic Diseases*, 2nd ed., Springer, Heidelberg, 2003, p. 28.
- [2] J.T.R. Clarke, *A Clinical Guide to Inherited Metabolic Diseases*, 3rd ed., Cambridge University Press, Cambridge, 2005.
- [3] A.B. Burlina, L. Bonafé, F. Zacchello, *Semin. Perinatol.* 23 (1999) 162.
- [4] H.M. Liebich, *J. Chromatogr.* 379 (1986) 347.
- [5] L.J. Hoffer, A. Taveroff, L. Robitaille, O.A. Mamer, M.L.J. Reimer, *J. Nutr.* 123 (1993) 1513.
- [6] L. Laffel, *Diabetes Metab. Res. Rev.* 15 (1999) 412.
- [7] J.J. Brière, J. Favier, A.P. Gimenez-Roqueplo, P. Rustin, *Am. J. Physiol. Cell Physiol.* 291 (2006) C1114.
- [8] B.E. Baysal, *Drug Discov. Today Dis. Mech.* 2 (2005) 247.
- [9] K.K. Pasikanti, P.C. Ho, E.C.Y. Chan, *J. Chromatogr. B* 871 (2008) 202.
- [10] T. Niwa, *J. Chromatogr.* 379 (1986) 313.
- [11] S. Hori, S. Nishiumi, K. Kobayashi, M. Shinohara, Y. Hatakeyama, Y. Kotani, N. Hatano, Y. Maniwa, W. Nishio, T. Bamba, E. Fukusaki, T. Azuma, T. Takenawa, Y. Nishimura, M. Yoshida, *Lung Cancer* 74 (2011) 284.
- [12] L. Yang, R.S. Kombu, T. Kasumov, S.H. Zhu, A.V. Cendrowski, F. David, V.E. Anderson, J.K. Kelleher, H. Brunengraber, *J. Biol. Chem.* 283 (2008) 21978.
- [13] C. Denkert, J. Budczies, T. Kind, W. Weichert, P. Tablack, J. Sehouli, S. Niesporek, D. Könsen, M. Dietel, O. Fiehn, *Cancer Res.* 66 (2006) 10795.
- [14] O. Fiehn, J. Kopka, R.N. Trethewey, L. Willmitzer, *Anal. Chem.* 72 (2000) 3573.
- [15] K.R. Kim, H.G. Park, M.J. Paik, H.S. Ryu, K.S. Oh, S.W. Myung, H.M. Liebich, *J. Chromatogr. B* 712 (1998) 11.
- [16] M.J. Paik, K.R. Kim, *J. Chromatogr. A* 1034 (2004) 13.
- [17] M.J. Paik, H.J. Lee, K.R. Kim, *J. Chromatogr. B* 821 (2005) 94.
- [18] M.J. Paik, E.Y. Cho, H. Kim, K.R. Kim, S. Choi, Y.H. Ahn, G. Lee, *Biomed. Chromatogr.* 22 (2008) 450.
- [19] Thermo Scientific Pierce: *GC and HPLC Technical Handbook*, Thermo Fisher Scientific Inc., 2008.
- [20] S. Nishiumi, M. Shinohara, A. Ikeda, T. Yoshie, N. Hatano, S. Kakuyama, S. Mizuno, T. Sanuki, H. Kutsumi, E. Fukusaki, T. Azuma, T. Takenawa, M. Yoshida, *Metabolomics* 6 (2010) 518.